Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 16, 2007 - Issue 6
Submit an article Journal homepage
495
Views
52
CrossRef citations to date
0
Altmetric
Perspective

Aripiprazole acts as a selective dopamine D2 receptor partial agonist

Martyn Wood GlaxoSmithKline, Schizophrenia and Bipolar Neurophysiology and Pharmacology, Psychiatry CEDD, Third Avenue, Harlow, Essex, CM19 5AW, UK
&
Charlie Reavill GlaxoSmithKline, Schizophrenia and Bipolar Neurophysiology and Pharmacology, Psychiatry CEDD, Third Avenue, Harlow, Essex, CM19 5AW, UK
Pages 771-775 | Published online: 15 May 2007

Citations (52)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Georgios D. Kotzalidis, Chiara Rapinesi, Chiara Chetoni & Sergio De Filippis. (2021) Aripiprazole IM depot as an option for the treatment of bipolar disorder. Expert Opinion on Pharmacotherapy 22:11, pages 1407-1416.
Read now
Wan Sarah Samiun, Siti Efliza Ashari, Norazlinaliza Salim & Syahida Ahmad. (2020) Optimization of Processing Parameters of Nanoemulsion Containing Aripiprazole Using Response Surface Methodology. International Journal of Nanomedicine 15, pages 1585-1594.
Read now
Hamid Reza Fard Masoumi, Mahiran Basri, Wan Sarah Samiun, Zahra Izadiyan & Chaw Jiang Lim. (2015) Enhancement of encapsulation efficiency of nanoemulsion-containing aripiprazole for the treatment of schizophrenia using mixture experimental design. International Journal of Nanomedicine 10, pages 6469-6476.
Read now
Daniel Huys, Katja Hardenacke, Pia Poppe, Christina Bartsch, Burak Baskin & Jens Kuhn. (2012) Update on the role of antipsychotics in the treatment of Tourette syndrome. Neuropsychiatric Disease and Treatment 8, pages 95-104.
Read now

Articles from other publishers (48)

Thian-Sze Wong, Guangzhi Li, Shiliang Li, Wei Gao, Geng Chen, Shiyi Gan, Manzhan Zhang, Honglin Li, Song Wu & Yang Du. (2023) G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. Signal Transduction and Targeted Therapy 8:1.
Crossref
Hugues Lamothe, Christiane Schreiweis, Lizbeth Sirenia Mondragón-González, Sana Rebbah, Oriana Lavielle, Luc Mallet & Eric Burguière. (2023) The Sapap3−/− mouse reconsidered as a comorbid model expressing a spectrum of pathological repetitive behaviours. Translational Psychiatry 13:1.
Crossref
Breana Channer, Stephanie M. Matt, Emily A. Nickoloff-Bybel, Vasiliki Pappa, Yash Agarwal, Jason Wickman & Peter J. Gaskill. (2023) Dopamine, Immunity, and Disease. Pharmacological Reviews 75:1, pages 62-158.
Crossref
Pierre-Michel Llorca, Philippe Nuss, Éric Fakra, Isabelle Alamome, Dominique Drapier, Wissam El Hage, Renaud Jardri, Stéphane Mouchabac, Marc Rabbani, Nicolas Simon, Marie-Noëlle Vacheron & Jean-Michel Azorin. (2022) Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. BMC Psychiatry 22:1.
Crossref
Ken W. Grasing, Kim Burnell & Alok De. (2022) Biphasic reward effects are characteristic of both lorcaserin and drugs of abuse: implications for treatment of substance use disorders. Behavioural Pharmacology 33:4, pages 238-248.
Crossref
Ana Jalles, Cármen Vieira, Joana Pereira-Sousa, Daniela Vilasboas-Campos, Ana Francisca Mota, Sara Vasconcelos, Bruna Ferreira-Lomba, Marta Daniela Costa, Jorge Diogo Da Silva, Patrícia Maciel & Andreia Teixeira-Castro. (2022) Aripiprazole Offsets Mutant ATXN3-Induced Motor Dysfunction by Targeting Dopamine D2 and Serotonin 1A and 2A Receptors in C. elegans. Biomedicines 10:2, pages 370.
Crossref
Michel Sáenz-Farret & Carlos Zúñiga-Ramírez. (2021) Aripiprazole in Meige Syndrome: Clinical Response and Implications for Treatment Development. Clinical Neuropharmacology 44:6, pages 225-228.
Crossref
Radomir Juza, Kristyna Stefkova, Wim Dehaen, Alena Randakova, Tomas Petrasek, Iveta Vojtechova, Tereza Kobrlova, Lenka Pulkrabkova, Lubica Muckova, Marko Mecava, Lukas Prchal, Eva Mezeiova, Kamil Musilek, Ondrej Soukup & Jan Korabecny. (2021) Synthesis and In Vitro Evaluation of Novel Dopamine Receptor D2 3,4-dihydroquinolin-2(1H)-one Derivatives Related to Aripiprazole. Biomolecules 11:9, pages 1262.
Crossref
Verena Sichert & Hans-Peter Volz. (2020) Rapid efficacy of aripiprazole in the treatment of catatonic depression/catatonia with consideration of the drug’s unique receptor profile: a case report. Fortschritte der Neurologie · Psychiatrie 89:04, pages 178-181.
Crossref
Louiza Belkacemi & Nissar A. Darmani. (2020) Dopamine receptors in emesis: Molecular mechanisms and potential therapeutic function. Pharmacological Research 161, pages 105124.
Crossref
V. I. Kozlovskiy, D. N. Kosterin & M. Yu. Popov. (2019) The role of agonistic/antagonistic activity in the development of psychotropic effects of antipsychotics. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY:1, pages 3-7.
Crossref
Sonya Besagar, Hannah L. Radabaugh, Isabel H. Bleimeister, Elizabeth A. Meyer, Peter J. Niesman, Jeffrey P. Cheng, Corina O. Bondi & Anthony E. Kline. (2019) Aripiprazole and environmental enrichment independently improve functional outcome after cortical impact injury in adult male rats, but their combination does not yield additional benefits. Experimental Neurology 314, pages 67-73.
Crossref
Chen-Cheng Lin, Hsin-An Chang, Yueh-Ming Tai, Tsung-Yen Chen, Fang-Jung Wan, Chuan-Chia Chang, Che-Se Tung & Yia-Ping Liu. (2019) Subchronic administration of aripiprazole improves fear extinction retrieval of Pavlovian conditioning paradigm in rats experiencing psychological trauma. Behavioural Brain Research 362, pages 181-187.
Crossref
Jiamei Lian & Chao Deng. (2019) Early antipsychotic exposure affects NMDA and GABAA receptor binding in the brains of juvenile rats. Psychiatry Research 273, pages 739-745.
Crossref
R. A. Nolan, R. Muir, K. Runner, E. K. Haddad & P. J. Gaskill. (2018) Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders. Journal of Neuroimmune Pharmacology 14:1, pages 134-156.
Crossref
Susan F. Sonnenschein, Kathryn M. Gill & Anthony A. Grace. (2018) State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia. Neuropsychopharmacology 44:3, pages 572-580.
Crossref
Jeffrey P. Cheng, Jacob B. Leary, Darik A. O’Neil, Elizabeth A. Meyer, Kristin E. Free, Corina O. Bondi & Anthony E. Kline. (2018) Spontaneous recovery of traumatic brain injury-induced functional deficits is not hindered by daily administration of lorazepam. Behavioural Brain Research 339, pages 215-221.
Crossref
Thomas I. Phelps, Corina O. Bondi, Vincent V. Mattiola & Anthony E. Kline. (2016) Relative to Typical Antipsychotic Drugs, Aripiprazole Is a Safer Alternative for Alleviating Behavioral Disturbances After Experimental Brain Trauma. Neurorehabilitation and Neural Repair 31:1, pages 25-33.
Crossref
Jiamei Lian, Bo Pan & Chao Deng. (2016) Early antipsychotic exposure affects serotonin and dopamine receptor binding density differently in selected brain loci of male and female juvenile rats. Pharmacological Reports 68:5, pages 1028-1035.
Crossref
Hsing-Cheng Liu, Shu-Yu Yang, Ya-Tang Liao, Chiao-Chicy Chen & Chian-Jue Kuo. (2016) Antipsychotic Medications and Risk of Acute Coronary Syndrome in Schizophrenia: A Nested Case-Control Study. PLOS ONE 11:9, pages e0163533.
Crossref
Yuji Odagaki, Masakazu Kinoshita & Toshio Ota. (2016) Comparative analysis of pharmacological properties of xanomeline and N -desmethylclozapine in rat brain membranes . Journal of Psychopharmacology 30:9, pages 896-912.
Crossref
Haydyn Lloyd & Chao Deng. (2016) Interaction of Dopamine D2 and 5-HT1A Receptor Partial Agonism on Antipsychotic Efficacy. Journal of Clinical Psychopharmacology 36:2, pages 192-193.
Crossref
Wan Sarah Samiun, Mahiran Basri, Hamid Reza Fard Masoumi & Nurshafira Khairudin. (2016) The prediction of the optimum compositions of a parenteral nanoemulsion system loaded with a low water solubility drug for the treatment of schizophrenia by artificial neural networks. RSC Advances 6:17, pages 14068-14076.
Crossref
Dorothee Möller, Ismail Salama, Ralf C. Kling, Harald Hübner & Peter Gmeiner. (2015) 1,4-Disubstituted aromatic piperazines with high 5-HT2A/D2 selectivity: Quantitative structure-selectivity investigations, docking, synthesis and biological evaluation. Bioorganic & Medicinal Chemistry 23:18, pages 6195-6209.
Crossref
Hidetoshi Komatsu. (2015) Novel Therapeutic GPCRs for Psychiatric Disorders. International Journal of Molecular Sciences 16:12, pages 14109-14121.
Crossref
Nobue Kitanaka, Junichi Kitanaka, F. Scott HallMasaru Kayama, Hironobu Sugimori, George R. UhlMotohiko Takemura. (2015) Pretreatment or Posttreatment with Aripiprazole Attenuates Methamphetamine-induced Stereotyped Behavior in Mice. Journal of Experimental Neuroscience 9s1, pages JEN.S27733.
Crossref
Michael De Santis, Bo Pan, Jiamei Lian, Xu-Feng Huang & Chao Deng. (2014) Different effects of Bifeprunox, Aripiprazole, and Haloperidol on body weight gain, food and water intake, and locomotor activity in rats. Pharmacology Biochemistry and Behavior 124, pages 167-173.
Crossref
Ganesh Gopalakrishna, Arpit Aggarwal & John Lauriello. (2013) Long-Acting Injectable Aripiprazole. Clinical Schizophrenia & Related Psychoses 7:2, pages 87-92.
Crossref
Sung-Kook Jung & Jeong-Mo Song. (2012) Two Cases of Drug-induced Secondary Parkinsonism Treated with Sasang Constitutional Therapy. Journal of Sasang Constitutional Medicine 24:4, pages 109-119.
Crossref
Yinbo Zhang & Guangzhi Dai. (2012) Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first‐episode schizophrenia through 52 weeks follow‐up in China. Human Psychopharmacology: Clinical and Experimental 27:6, pages 605-614.
Crossref
Philip G. Strange. 2012. Targets and Emerging Therapies for Schizophrenia. Targets and Emerging Therapies for Schizophrenia 37 49 .
Andrea E Cavanna, Claudia Selvini, Cristiano Termine, Chiara Luoni, Clare M Eddy & Hugh Rickards. (2011) Tolerability profile of aripiprazole in patients with Tourette syndrome. Journal of Psychopharmacology 26:6, pages 891-895.
Crossref
Jamie D. Croxtall. (2012) Aripiprazole. CNS Drugs 26:2, pages 155-183.
Crossref
Stefan Löber, Harald Hübner, Nuska Tschammer & Peter Gmeiner. (2011) Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates. Trends in Pharmacological Sciences 32:3, pages 148-157.
Crossref
Clare M. Eddy, Hugh E. Rickards & Andrea E. Cavanna. (2010) Treatment strategies for tics in Tourette syndrome. Therapeutic Advances in Neurological Disorders 4:1, pages 25-45.
Crossref
Martin A. Katzman. (2011) Aripiprazole: A clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness. Journal of Affective Disorders 128, pages S11-S20.
Crossref
Francesco Belardetti. (2010) Evolving therapeutic indications for N-type calcium channel blockers: from chronic pain to alcohol abuse. Future Medicinal Chemistry 2:5, pages 791-802.
Crossref
Ian P. Holmes, Richard J. Blunt, Olivier E. Lorthioir, Stephen M. Blowers, Andy Gribble, Andrew H. Payne, Ian G. Stansfield, Martyn Wood, Patrick M. Woollard, Charlie Reavill, Claire M. Howes, Fabrizio Micheli, Romano Di Fabio, Daniele Donati, Silvia Terreni, Dieter Hamprecht, Luca Arista, Angela Worby & Steve P. Watson. (2010) The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure. Bioorganic & Medicinal Chemistry Letters 20:6, pages 2013-2016.
Crossref
Chiara Cecchelli, Giacomo Grassi & Stefano Pallanti. (2010) Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression. Case Reports in Medicine 2010, pages 1-4.
Crossref
Dan MaPaul C Guest & Sabine Bahn. (2009) Metabonomic studies of schizophrenia and psychotropic medications: focus on alterations in CNS energy homeostasis. Bioanalysis 1:9, pages 1615-1626.
Crossref
Konstantinos N Fountoulakis & Eduard Vieta. (2009) Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Annals of General Psychiatry 8:1.
Crossref
Mei Han, Xu-Feng Huang & Chao Deng. (2009) Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. The International Journal of Neuropsychopharmacology 12:07, pages 941.
Crossref
Gerard A. McLoughlinDan MaTsz M. TsangDeclan N. C. JonesJackie CiliaMark D. HillMelanie J. RobbinsIsabel M. BenzelPeter R. MaycoxElaine HolmesSabine Bahn. (2009) Analyzing the Effects of Psychotropic Drugs on Metabolite Profiles in Rat Brain Using 1 H NMR Spectroscopy . Journal of Proteome Research 8:4, pages 1943-1952.
Crossref
J. Adan-Manes & P. Garcia-Parajua. (2009) Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. Journal of Clinical Pharmacy and Therapeutics 34:2, pages 245-246.
Crossref
Michele Fornaro, Filippo Gabrielli, Chiara Mattei, Valentina Vinciguerra & Pantaleo Fornaro. (2008) Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report. Annals of General Psychiatry 7:1.
Crossref
Johannes C.M. Schlachetzki & Jens M. Langosch. (2008) Aripiprazole Induced Hypersexuality in a 24-Year-Old Female Patient With Schizoaffective Disorder?. Journal of Clinical Psychopharmacology 28:5, pages 567-568.
Crossref
Marie-Odile Krebs. (2008) Développement d’un antipsychotique : nouvelles directions. Therapies 63:3, pages 257-262.
Crossref
Michael J. Marino, Lars J. S. Knutsen & Michael Williams. (2008) Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era. Journal of Medicinal Chemistry 51:5, pages 1077-1107.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.